WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Download the WorkBoat Show App! Plan your schedule, explore exhibitors, and access event details anytime. Get the app › Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

151.44 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Which S&P500 stocks are gapping on Monday?
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Monday to uncover the stocks that are gapping in the S&P500 index. 
Via Chartmill
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human... 
Via MarketMinute
Topics Artificial Intelligence Derivatives
3 Low-Volatility Stocks That Concern Us
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
A Look Into Biogen Inc's Price Over Earnings
 
Via Benzinga
Looking Into Biogen's Recent Short Interest
 
Via Benzinga
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns
Boston, MA – October 1, 2025 – Biogen Inc. (NASDAQ: BIIB) saw its stock surge by an impressive 9.02% today, propelled by a wave of promising advancements in its Alzheimer's disease drug testing... 
Via MarketMinute
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs. 
Via Benzinga
Topics Government
Wednesday's session: top gainers and losers in the S&P500 index
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Dow Futures Defy Shutdown Fears: A Deep Dive into Market Resilience
As the U.S. government teeters on the brink of another shutdown, a seemingly counter-intuitive phenomenon is gripping financial markets: Dow futures are not only holding steady but are showing signs of... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
From Biogen Inc.
Via GlobeNewswire
Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays
Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29,... 
Via MarketMinute
Topics Artificial Intelligence Earnings
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy
On Tuesday, the U.S. 
Via Benzinga
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Biogen
 
Via Benzinga
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
From Biogen Inc.
Via GlobeNewswire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment
Biogen will integrate Alcyone's team and divest the remaining assets into Neela Therapeutics as part of its $85 million acquisition. 
Via Benzinga
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
From Biogen Inc.
Via GlobeNewswire
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence
1 of Wall Street’s Favorite Stock Worth Your Attention and 2 That Underwhelm
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy
Biogen (BIIB) Stock Trades Down, Here Is Why
Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.